Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q7Z6K3
UPID:
PTAR1_HUMAN
Alternative names:
-
Alternative UPACC:
Q7Z6K3; Q5T7V5; Q5T7V6
Background:
Protein prenyltransferase alpha subunit repeat-containing protein 1, identified by the accession number Q7Z6K3, plays a crucial role in the prenylation process. This biochemical pathway is essential for the post-translational modification of various proteins, facilitating their attachment to cell membranes and influencing their function and interaction within cellular environments.
Therapeutic significance:
Understanding the role of Protein prenyltransferase alpha subunit repeat-containing protein 1 could open doors to potential therapeutic strategies. Its involvement in the prenylation process makes it a compelling target for drug discovery, aiming to modulate protein interactions and functions that are critical in cellular signaling pathways.